| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8cdfbc70d9776e1ea4502b21128b30c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14ff083cfde502b99517c488b8e38df6 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-34 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2009-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d0d1a212c3efa66cf33cf233a90cd45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8576155369085ad942d2ecb698f059c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dec8589cb5f9df57546cfc8c5906c330 |
| publicationDate |
2010-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010229038-A |
| titleOfInvention |
Anticancer drugs for triple negative breast cancer |
| abstract |
An object of the present invention is to provide a therapeutic agent capable of effectively treating triple negative breast cancer exhibiting estrogen receptor expression negative, progesterone receptor expression negative, and HER2 expression negative. By using CRM197 or a variant thereof as an active ingredient of the anticancer agent for triple negative breast cancer, effective treatment of triple negative breast cancer that could not be solved by conventional techniques is realized. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114404398-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10723794-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11629186-B2 |
| priorityDate |
2009-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |